QLGN
Price
$1.84
Change
+$0.08 (+4.55%)
Updated
Aug 7, 04:29 PM (EDT)
Capitalization
2.88M
ZLDAF
Price
$0.26
Change
-$0.00 (-0.00%)
Updated
Aug 5 closing price
Capitalization
3.16M
Interact to see
Advertisement

QLGN vs ZLDAF

Header iconQLGN vs ZLDAF Comparison
Open Charts QLGN vs ZLDAFBanner chart's image
Qualigen Therapeutics
Price$1.84
Change+$0.08 (+4.55%)
Volume$300
Capitalization2.88M
Zelira Therapeutics
Price$0.26
Change-$0.00 (-0.00%)
Volume$2.04K
Capitalization3.16M
QLGN vs ZLDAF Comparison Chart in %
Loading...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QLGN vs. ZLDAF commentary
Aug 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QLGN is a Buy and ZLDAF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 07, 2025
Stock price -- (QLGN: $1.76 vs. ZLDAF: $0.26)
Brand notoriety: QLGN and ZLDAF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QLGN: 7% vs. ZLDAF: 253%
Market capitalization -- QLGN: $2.88M vs. ZLDAF: $3.16M
QLGN [@Biotechnology] is valued at $2.88M. ZLDAF’s [@Biotechnology] market capitalization is $3.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $210.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QLGN’s FA Score shows that 1 FA rating(s) are green whileZLDAF’s FA Score has 0 green FA rating(s).

  • QLGN’s FA Score: 1 green, 4 red.
  • ZLDAF’s FA Score: 0 green, 5 red.
According to our system of comparison, QLGN is a better buy in the long-term than ZLDAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QLGN’s TA Score shows that 3 TA indicator(s) are bullish while ZLDAF’s TA Score has 3 bullish TA indicator(s).

  • QLGN’s TA Score: 3 bullish, 6 bearish.
  • ZLDAF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ZLDAF is a better buy in the short-term than QLGN.

Price Growth

QLGN (@Biotechnology) experienced а -30.02% price change this week, while ZLDAF (@Biotechnology) price change was -0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +8.67%, and the average quarterly price growth was +12.54%.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDAF($3.16M) has a higher market cap than QLGN($2.88M). ZLDAF YTD gains are higher at: -32.742 vs. QLGN (-58.195). ZLDAF has higher annual earnings (EBITDA): -3.17M vs. QLGN (-6.73M). ZLDAF has higher revenues than QLGN: ZLDAF (40.9K) vs QLGN (0).
QLGNZLDAFQLGN / ZLDAF
Capitalization2.88M3.16M91%
EBITDA-6.73M-3.17M212%
Gain YTD-58.195-32.742178%
P/E Ratio0.00N/A-
Revenue040.9K-
Total Cash388KN/A-
Total Debt1.43MN/A-
FUNDAMENTALS RATINGS
QLGN vs ZLDAF: Fundamental Ratings
QLGN
ZLDAF
OUTLOOK RATING
1..100
9590
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9785
P/E GROWTH RATING
1..100
48100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QLGN's Valuation (25) in the null industry is in the same range as ZLDAF (40). This means that QLGN’s stock grew similarly to ZLDAF’s over the last 12 months.

QLGN's Profit vs Risk Rating (100) in the null industry is in the same range as ZLDAF (100). This means that QLGN’s stock grew similarly to ZLDAF’s over the last 12 months.

QLGN's SMR Rating (100) in the null industry is in the same range as ZLDAF (100). This means that QLGN’s stock grew similarly to ZLDAF’s over the last 12 months.

ZLDAF's Price Growth Rating (85) in the null industry is in the same range as QLGN (97). This means that ZLDAF’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's P/E Growth Rating (48) in the null industry is somewhat better than the same rating for ZLDAF (100). This means that QLGN’s stock grew somewhat faster than ZLDAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QLGNZLDAF
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
40%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 29 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOCN36.471.66
+4.77%
DigitalOcean Holdings
MDB235.827.57
+3.32%
MongoDB
XIN1.930.03
+1.58%
Xinyuan Real Estate Co Ltd
HSTM26.090.35
+1.36%
HealthStream
ICG2.74N/A
N/A
Intchains Group Limited

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with NTLA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
-7.37%
NTLA - QLGN
35%
Loosely correlated
-1.81%
PHIO - QLGN
32%
Poorly correlated
-0.85%
ZLDAF - QLGN
29%
Poorly correlated
N/A
MNOV - QLGN
28%
Poorly correlated
N/A
JAGX - QLGN
28%
Poorly correlated
-0.22%
More